Lv6
1800 积分 2022-09-19 加入
A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy
3天前
已完结
Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan
14天前
已完结
Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study
17天前
已完结
Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study
19天前
已完结
Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study)
28天前
已完结
Outcome and risk factors for progression in IgG4-related disease under watchful waiting
28天前
已完结
Treatment strategies for relapsing IgG4-RD: twelve-year experience from a prospective cohort
28天前
已完结
A phase 2 trial of rilzabrutinib in IgG4-related disease
1个月前
已完结
THU0158 ‘ONE IS NOT ENOUGH’ - RITUXIMAB SINGLE VS DOUBLE INFUSION PROTOCOL IN TREATMENT OF ESTABLISHED RHEUMATOID ARTHRITIS – REAL LIFE EXPERIENCE OF GARTNAVEL GENERAL HOSPITAL, GLASGOW, UK
1个月前
已完结
Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial
1个月前
已完结
皖公网安备34019202002308
